CA-CROWN-BIOSCIENCE
8.10.2020 14:02:15 CEST | Business Wire | Press release
Crown Bioscience today announces the appointment of Pam Shang as vice president for global quality. Mrs. Shang will be instrumental in further enhancing global quality across the company, leveraging her deep expertise in implementing quality systems for pharma and biotechnology clients including in GLP, GMP and other regulated environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005432/en/
Building on CrownBio’s existing platforms, Mrs. Shang will be responsible for the strategic direction, enhancement, and growth of CrownBio’s quality systems, underlying organizational processes, and leading the associated change management.
“I am excited to welcome Pam to the leadership team,” said Armin Spura, PhD, chief executive officer of CrownBio. “With her wealth of experience in implementing global quality systems and overseeing GxP initiatives, Pam will ensure that CrownBio puts quality and our customers at the forefront of all CrownBio initiatives”.
Mrs. Shang joins CrownBio from Asahi Kasei America, a Japanese pharmaceutical company, where she was head of global quality and compliance. Pam was responsible for all regulatory matters across diverse areas including quality oversight and control, regulatory compliance, and audit management.
CrownBio has seen consistent quality improvements year-on-year, with associated enhanced client satisfaction. The new strategic initiatives led by Mrs. Shang across global operational platforms will ensure high scientific quality and a continued dedication to enhance standards and performance across the company.
“I’m delighted to bring my expertise to CrownBio”, said Pam Shang. “The quality of our work and compliance to regulatory standards is extremely important, and pivotal for CrownBio’s continued growth. My aim is to ensure that all staff are empowered with proper resources and regulatory knowledge to be successful and accountable, to foster a success-oriented, safe working environment and to ensure the scientific quality of our products and services”.
Mrs. Shang holds a BS in Management Information Systems and a minor in Business from Southern Illinois University. She also completed Master’s Program course requirements in Biotechnology at Harvard University.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
View source version on businesswire.com: https://www.businesswire.com/news/home/20201008005432/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM, a Global Leader in Quantum Computing, and Real Asset Acquisition Corp. Announce Upsized USD 146 million PIPE with New Commitment from Ilmarinen2.6.2026 16:17:00 CEST | Press release
IQM in conjunction with its SPAC partner, Real Asset Acquisition Corp., increased commitments to its PIPE due to upsized demand. This additional commitment comes from a new investor, Ilmarinen, one of Finland’s largest private earnings-related pension insurance companies. This brings total PIPE commitments from leading new and existing investors to over USD 146 million. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and a cash position expected to be up to EUR 406 million (USD 477 million1). Significant business momentum, with 2025 revenue of EUR 31 million (USD 36 million2). IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”) and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced an additional PIPE commitment from Ilmarinen in connection with the previously announced business combination between IQM and RAA
Laserfiche Launches on AWS Marketplace, Bringing Intelligent Content Management to the Enterprise2.6.2026 16:00:00 CEST | Press release
Organizations can now seamlessly procure Laserfiche document management to support and scale information governance and workflow automation. Laserfiche — the leading SaaS provider of intelligent content management — has partnered with AWS to make Laserfiche available through AWS Marketplace. This collaboration enables AWS customers to seamlessly procure Laserfiche’s document management platform to manage content, automate workflows and implement agentic AI capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602537198/en/ Laserfiche intelligent content management is now available to procure directly through AWS Marketplace. “We’re excited about this evolution of our long-standing partnership with AWS,” said Thomas Phelps, Laserfiche senior vice president of corporate strategy and CIO. “AWS Marketplace provides a near-frictionless experience for Laserfiche direct customers who want to accept negotiated private offe
Experian Brings Trusted Agentic AI to Financial Services With the Launch of Agent Operating System™2.6.2026 15:05:00 CEST | Press release
A new core capability within Experian’s Ascend Platform, designed to help financial services organisations safely scale agentic AI across the lending lifecycleBrings together Experian, client and partner AI agents within a trusted operating layer for data, decisioning, governance and control55% of consumers say they would allow an AI agent to make an autonomous purchase on their behalfServiceNow becomes first partner to integrate with Experian’s Agent Operating System Experian today announces the launch of the Agent Operating System™, a trusted agentic AI layer within the Experian Ascend Platform, unveiled at Money20/20 Europe. The Experian Agent Operating System is designed to help financial services organisations move successfully beyond AI experimentation and safely scale agentic AI to transform decision-making, customer experiences, and day-to-day operations. It enables AI agents from Experian, clients and partners to work together through a common trust, semantic and orchestration
Lenovo Technology Powers FIFA World Cup 2026™ Operations and Strengthens AI-Driven Broadcast2.6.2026 15:00:00 CEST | Press release
Lenovo’s Near Real-Time AI Infrastructure Enables IPTV Delivery, Operational Control, and Transformative Fan Experiences at Unprecedented Global Scale Lenovo today announced it is delivering a near real-time AI-powered infrastructure platform for the FIFA World Cup 2026™ to enable ultra-low-latency IPTV (Internet Protocol Television) video distribution in addition to the traditional cable and satellite broadcast, intelligent content delivery, and mission-critical decision-making across the event ecosystem and operations. As the world’s largest sporting event prepares for an unprecedented scale—spanning three host countries, featuring 48 teams, and engaging an estimated 6 billion fans—FIFA, broadcasters, and event operators will benefit from a live, always-on environment designed to perform at the highest level. As FIFA’s Official Technology Partner, Lenovo will deploy servers at the International Broadcast Center in Dallas, Texas, to help deliver the computing power, devices, and AI-dr
High Q Technologies and Creative Biostructure Announce Strategic Partnership Expanding Global Access to Quantum-Enabled EPR Spectroscopy2.6.2026 15:00:00 CEST | Press release
Collaboration Aims to Accelerate Adoption of EPR Spectroscopy in Structural Biology and Drug Discovery High Q Technologies, a developer of quantum-enabled electron paramagnetic resonance (EPR) spectroscopy systems, and Creative Biostructure, a structural biology Contract Research Organization, today announced a strategic partnership to support broader adoption of EPR spectroscopy for studying protein dynamics in pharmaceutical and biotechnology research. EPR spectroscopy is increasingly relevant as drug discovery turns toward disordered, flexible, and disease‑relevant protein systems that cannot be fully understood through static structural methods alone. However, broad adoption of EPR has historically been limited by instrument and workflow complexity, and the need for dedicated technical expertise in experimental design and data interpretation. Leveraging quantum sensor technology, FATHOM® EPR has overcome these challenges. By providing unique measurements of long‑range distances, FA
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom